AAVATAR Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $3.68M

  • Investors
  • 12

AAVATAR Therapeutics General Information

Description

Developer of an intelligent gene therapy platform intended to treat rare diseases. The company's technology utilizes artificial intelligence capsid engineering, machine-learning-based biological analysis, recombinant AAV production, in vivo screening, next-generation sequencing, and predictive modeling, enabling pharmaceutical companies to deliver gene therapies precisely to targeted tissues while reducing side effects and improving treatment efficiency.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 1023, Building B 540
  • Misa-daero, Hyundai Knowledge Industry Center Hangang Misa 2nd
  • Hanam, Gyeonggi 12925
  • South Korea
+82
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Corporate Office
  • Room 1023, Building B 540
  • Misa-daero, Hyundai Knowledge Industry Center Hangang Misa 2nd
  • Hanam, Gyeonggi 12925
  • South Korea
+82

AAVATAR Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AAVATAR Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B) 30-Sep-2026 $3.68M Completed Pre-Clinical Trials
8. Accelerator/Incubator 01-Jun-2026 Completed Pre-Clinical Trials
7. Accelerator/Incubator 01-May-2026 Completed Pre-Clinical Trials
6. Later Stage VC (Series A) 23-Oct-2025 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 07-Nov-2023 Completed Pre-Clinical Trials
4. Early Stage VC 01-Aug-2022 Completed Pre-Clinical Trials
3. Accelerator/Incubator 01-Dec-2021 Completed Pre-Clinical Trials
2. Seed Round 01-May-2021 Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view AAVATAR Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AAVATAR Therapeutics Patents

AAVATAR Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12480098-B1 Adeno-associated virus variant Active 18-Oct-2024
US-20260109956-A1 Adeno-associated virus variant Pending 18-Oct-2024
EP-4768500-A1 Adeno-associated virus variants Pending 18-Oct-2024
EP-4768500-A4 Adeno-associated virus variants Pending 18-Oct-2024
WO-2026084101-A1 Adeno-associated virus variants Pending 18-Oct-2024 C12N7/00
To view AAVATAR Therapeutics’s complete patent history, request access »

AAVATAR Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AAVATAR Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
HB Investment Venture Capital Minority
IBK Changgong Accelerator/Incubator
Regent Partners (Seoul) Venture Capital Minority
Shinhan Capital Venture Capital Minority
Smilegate Investment Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

AAVATAR Therapeutics FAQs

  • When was AAVATAR Therapeutics founded?

    AAVATAR Therapeutics was founded in 2020.

  • Where is AAVATAR Therapeutics headquartered?

    AAVATAR Therapeutics is headquartered in Hanam, South Korea.

  • What is the size of AAVATAR Therapeutics?

    AAVATAR Therapeutics has 18 total employees.

  • What industry is AAVATAR Therapeutics in?

    AAVATAR Therapeutics’s primary industry is Drug Delivery.

  • Is AAVATAR Therapeutics a private or public company?

    AAVATAR Therapeutics is a Private company.

  • What is AAVATAR Therapeutics’s current revenue?

    The current revenue for AAVATAR Therapeutics is .

  • How much funding has AAVATAR Therapeutics raised over time?

    AAVATAR Therapeutics has raised $7.39M.

  • Who are AAVATAR Therapeutics’s investors?

    HB Investment, IBK Changgong, Regent Partners (Seoul), Shinhan Capital, and Smilegate Investment are 5 of 12 investors who have invested in AAVATAR Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process